NEUE
NeueHealth, Inc.6.75
+0.00+0%
Oct 3, 9:43:31 AM EDT
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
60.94MP/E (TTM)
-Basic EPS (TTM)
-17.65Dividend Yield
0%Recent Filings
8-K
NeueHealth merger closes, goes private
NeueHealth closed its merger with an NEA affiliate on October 2, 2025, at $7.33 per share in cash, totaling $22.3 million paid to stockholders, while key investors rolled over equity for private ownership. The deal, funded partly by expanding an NEA credit facility, triggered NYSE delisting and ends public reporting. Lenders also funded $25 million in tranche 2A loans under an amended agreement, boosting liquidity to $95 million available amid tighter cash covenants starting at $25 million. Going private sharpens focus on value-driven care, yet merger risks linger.
8-K
Merger outside date extended
8-K
NeueHealth Q2 profit surges
NeueHealth reported Q2 2025 results on August 7, showing revenue of $209 million and net income from continuing operations of $6.8 million, a sharp turnaround from last year's $39 million loss. Adjusted EBITDA hit $19 million, marking the sixth straight profitable quarter, while serving 694,000 consumers—up 45% year-over-year—via its value-based care model. Momentum builds across ACA, Medicare, and Medicaid segments. Yet risks loom from a pending merger with NEA affiliates.
10-Q
Q2 FY2025 results
NeueHealth swung to an operating profit of $14.3M in Q2 FY2025 ended June 30, 2025, up from a $37.5M loss y/y, while YTD operating income hit $16.9M versus a $60.7M loss last year—driven by NeueCare's capitated revenue jumping 27% y/y to $82.5M on membership growth, though ACO REACH revenue dipped 23% y/y to $115.3M from fewer aligned beneficiaries. Medical costs fell 18% y/y to $307.3M YTD, lifting margins as restructuring trimmed operating costs 32% y/y to $93.5M; diluted EPS from continuing operations improved to $(3.49) YTD from $(8.77), reconciling to 8.75M weighted shares with anti-dilution from warrants and preferred stock. Cash climbed to $131.6M non-regulated, but total debt held at $212.4M across facilities maturing 2028; free cash flow not disclosed in the 10-Q. The pending NEA merger, approved by stockholders in May 2025, eyes full ownership by NEA funds—yet regulatory hurdles loom large.
8-K
Annual meeting results
NeueHealth's stockholders overwhelmingly elected its ten director nominees at the May 29, 2025 annual meeting, with votes ranging from 5.1 million to 5.2 million for amid 6.6 million shares represented. They ratified Deloitte & Touche as auditors for 2025 and approved 2024 executive pay on a non-binding basis, with 4.7 million in favor versus 525,000 against. Strong support signals board stability. No major dissent emerged.
ALHC
Alignment Healthcare, Inc.
20.03-0.08
ASTH
Astrana Health Inc.
22.31+0.01
CNC
Centene Corporation
38.97-1.48
CVS
CVS Health Corporation
78.29-1.40
EHSI
Elite Health Systems, Inc.
1.31-0.14
ELV
Elevance Health, Inc.
351.90-8.77
HUM
Humana Inc.
258.16-16.58
MOH
Molina Healthcare Inc
160.88-5.62
NUTX
Nutex Health Inc.
171.72-4.06
UNH
UnitedHealth Group Incorporated
334.20-6.90